tbuckley/cabot-search huggingface dataset:
Effectiveness of dermatologic evaluation in the management of cancer patients.
Authors: Matelda Medri, Elena Tenti, Daniele Andreis, Emanuela Scarpi, Dino Amadori, Ignazio Stanganelli
Journal: Journal of Clinical Oncology (2015)

e20651 Background: Epidermal growth factor receptor inhibitors (EGFRI) induce skin adverse events that can lead to psychosocial discomfort with a consequent reduction in quality of life, poor therapy adherence, dose interruption and sometimes treatment discontinuation. Optimum management of skin toxicity induced by targeted therapies is essential for patients to remain on prolonged therapies. We aimed to evaluate whether the involvement of a dermatologist can help to improve compliance to treatment. Methods: This was a retrospective, observational, uncontrolled, comparative study on 65 adults with different primary tumors showing skin toxicity from EGFRI treatment. The study population was divided into 2 groups: the first group of 30 patients was only evaluated by the oncology team while the second group ( 35 patients) was also assessed by an oncologist. Results: All 65 patients had developed one (67.6%) or more EGFRI-derived cutaneous (32.3%) adverse events (AE) including papulopustular eruption (69.2%), xerosis (23,0%), pruritus (15,3%), mucositis (76%) and paronychia (23.0%). There was no significant difference in severity of skin toxicity between groups ( grade 2-3 : 71.4% vs 56.7%). In the group evaluated by the dermatologist there were more skin manifestations in a higher number of patients (71.4% vs 56.7%), fewer patients showing severe skin toxicity (28.6% of patients with grade 3 AE vs. 14.2% with grade ≥ 4), fewer dose treatment reductions (8.6% vs 26.7% ) and fewer cases of permanent treatment discontinuation ( 0 vs 13.3% ) (p = 0.041) . Conclusions: The multidisciplinary management (oncologist + dermatologist) of skin toxicity is more effective than oncologist-only management.
Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in previously treated patients with malignant pleural mesothelioma (MPM) enrolled in the NGR015 phase 3 trial.
Authors: Alessandra Bulotta, Vanesa Gregorc, Maria G Viganò, Gilda Rossoni, Floriana Fontana, Cristina Ammannati, Scialini Colombi, Antonio Lambiase, Claudio Bordignon
Journal: Journal of Clinical Oncology (2015)

7558 Background: NGR-hTNF, a tumor-targeted antivascular agent, promotes a vessel normalization that improves intratumor T-cell infiltration and chemotherapy uptake. The prognostic role of baseline blood NLR, an index of host immune response to tumor, has inconsistently been reported in retrospective MPM series. We assessed NLR in a homogenous population receiving systemic therapy after failure of first-line pemetrexed-based regimen. Methods: We used NLR data from patients randomly assigned in the NGR015 trial to receive NGR-hTNF (n = 200) or placebo (n = 200) both given with best investigator choice (BIC: gemcitabine, vinorelbine, doxorubicin or supportive care). The prognostic effects of NLR splitted at sample median (4; 95% CI, 4 to 4) were tested exclusively in the NGR015 placebo arm through Cox models adjusted for age, sex, PS, histology, EORTC score, prior disease control and treatment-free interval (TFI). In patients with short TFI ( < median of 4.8 months), the addition of NGR-hTNF to BIC was associated with increased OS (p = 0.02) and PFS (p = 0.02) compared with placebo plus BIC. Results: NLR was univariately related to survival, along with TFI, histology, EORTC score and prior disease control. In multivariate models, high NLR (HR = 1.95; p < 0.0001), short TFI (HR = 1.98; p < 0.0001), nonepithelial histology (HR = 1.63; p = 0.02) and poor EORTC score (HR = 1.73; p = 0.02) remained independently associated with worse OS. Median OS in low and high NLR subsets was 9.5 and 6.3 months, respectively. Patients with low NLR resulted more sensitive to NGR-hTNF effects as measured by PFS (HR = 0.74) than those with high NLR (HR = 1.19; interaction p-value = 0.03). In patients with low NLR (n = 174), NGR-hTNF plus BIC vs placebo plus BIC tended to improve PFS (5.5 vs 2.8 months; p = 0.06). In patients with low NLR and short TFI (n = 88), NGR-hTNF plus BIC vs placebo plus BIC significantly increased PFS (5.5 vs 2.3 months; p = 0.04) and OS (17.2 vs 8.4 months; p = 0.007). Conclusions: NLR is an independent prognostic factor in pretreated MPM. A low NLR predicts benefit with NGR-hTNF in patients with short TFI who had a rapidly progressing disease after first-line therapy. Clinical trial information: NCT01098266.
FRI-195-Long-term effect of nucleos (t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients
Authors: Kenichi Morikawa, Machiko Umemura, Koji Ogawa, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Tomoe Shimazaki, Megumi Kimura, Takaaki Izumi, Masato Nakai, Takuya Sho, Goki Suda, Mitsuteru Natsuizaka, Kota Ono, Kazumoto Murata, Masaya Sugiyama, Mizokami Masashi, Naoya Sakamoto
Journal: Journal of Hepatology (2019)
FRI-174-Discovery of novel therapeutic targets for decreasing HBsAg, focusing on host proteins binding to HBV RNAs
Authors: Ryota Haba, Kazuki Shimane, Takaki Kawano, Nozomi Nakajima, Toshiyuki Nakatani, Shingo Mizunaga, Shinji Hagiwara, Takefumi Hara, Yasuhito Tanaka
Journal: Journal of Hepatology (2019)
FRI-129-A defect in the Nrf2/HO-1 pathway and Nox2 activation results in regulatory T cell mitochondrial dysfunction in alcohol related cirrhosis
Authors: Niloufar Safinia, Trishan Vaikunthanathan, Silvia Cellone Trevelin, Marco Romano, Qi Peng, Mark Thursz, Alberto Sanchez-Fueyo, Robert Lechler, Giovanna Lombardi
Journal: Journal of Hepatology (2019)
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
Authors: Beckey Trinh, Guacimara Ortega Sanchez, Petra Herzig, Heinz Läubli
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Treatment with a combination of PD-1 and CTLA-4 targeted checkpoint inhibition has improved outcome of melanoma patients and led to durable remissions but is also associated with significant toxicities. Endocrinopathies such as thyroiditis and hypophysitis are often seen, but other, rarer disturbances have also been described. Endocrinopathies affecting the parathyroid gland are&nbsp;rarely reported and no clear pathomechanism has been proposed. <h3>Case presentation</h3> Here, we report a case of severe hypocalcemia due to an antibody-mediated hypoparathyroidism as an immune-related adverse event (irAE) in a patient who was treated with the anti-PD-1 antibody nivolumab and anti-CTLA-4 antibody ipilimumab. Hypocalcemia was rapidly corrected by substitution, but the endogenous serum parathyroid hormone (PTH) remained low. The patient demonstrated a rapid and profound tumor response to the combination immune checkpoint blockade, but developed a severe colitis that required high-dose intravenous corticosteroid and anti-TNFα therapy. During this strong immunosuppression the PTH level normalized and the calcium levels were stable without substitution. However, during tapering of immunosuppressants, the PTH and calcium levels decreased again to a level requiring calcium substitution. <h3>Conclusion</h3> Our report demonstrates a rare endocrinopathy as a complication of combined PD-1 and CTLA-4 blockade. In addition, it provides evidence from the course of the disease that inflammation within the parathyroid gland is involved in the mechanism.
TCTAP A-126 Patients Undergoing Elective Lower Extremity Revascularization Have High Prevalence of Silent Coronary Ischemia
Authors: Dainis Krievins, Indulis Kumsars, Edgars Zellans, Roberts Rumba, Ligita Zvaigzne, Gustavs Latkovskis, Christopher K. Zarins, Andrejs Erglis
Journal: Journal of the American College of Cardiology (2019)
Decontamination Strategies for Critically Ill Patients
Authors: Nia Taylor, Hans Rommes, Hendrick van Saene
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI-417-Impact of a nurse educational program and accessibility in the management of patients with hepatocellular carcinoma under systemic treatment
Authors: Neus Llarch, Gemma Iserte, Víctor Sapena, Alvaro Diaz-Gonzalez, Marco Sanduzzi Zamparelli, Leonardo Gomes da Fonseca, Cassia Regina G Leal, Jordi Bruix, Maria Reig
Journal: Journal of Hepatology (2019)
The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
Authors: Afsar A. Mian, Ines Baumann, Marcus Liebermann, Florian Grebien, Giulio Superti-Furga, Martin Ruthardt, Oliver G. Ottmann, Oliver Hantschel
Journal: Leukemia (2019)
SAT-413-Selected cytokines associated with chronic hepatitis b histological activity and fibrosis: A 78-week prospective study
Authors: Xiao-Qin Dong, yongqiong Deng, Jiyuan Zhou, Linlin Yan, Zhao Wu, liang miao, Wanna Yang, Tiantian Yao, Hong Zhao, Gui-Qiang Wang
Journal: Journal of Hepatology (2019)
Selective indications of surgery in esophageal gastrointestinal stromal tumors: A retrospective study of the French Sarcoma Group (FSG).
Authors: Florence Duffaud, Pierre Meeus, Francois Bertucci, jean-Baptiste Delhorme, Eberhard Stoeckle, Nicolas Isambert, Emmanuelle Bompas, Johan Gagniere, Olivier Bouche, Maud Toulmonde, Sebastien Salas, Jean-Yves Blay, Sylvie Bonvalot
Journal: Journal of Clinical Oncology (2015)

10534 Background: Esophageal GIST (ESOGIST) are rare tumors, accounting for less than 1% of all GISTs, requiring special consideration regarding evaluation, diagnosis, perioperative treatment and conduct of operation. Methods: Through a national multicenter retrospective study in the FSG, 17 patients (pts) with localized ESOGIST were identified between 2000 and 2014 in 9 FSG centers. Results: Characteristics of pts were: 11 females, 6 males, median age of 69 years (36-81). Weight loss (n = 6), dysphagia (n = 5) were the most common symptoms. Eight (47%) tumors (T) occurred in the lower third of the esophagus, 5 (29%) in the gastro-oesophageal junction, 2 in the superior third, and 2 in the middle third. All pts underwent oesophagoscopy and/or endoscopic ultrasound (EUS) and CT scan. 15 had a pretherapeutic biopsy guided by EUS. Median T size was 70 mm (3-150). Nine pts received imatinib (IM) therapy as 1st treatment resulting in 6 PR, 3 SD, and permitting T resection in one. Tumors were resected in 8 (47%) pts, 7 upfront, one after IM; with enucleation in 4 [median size 4 cm (3-7)], oesophagectomy in 4 [median size 10 cm (0.5-15)]. Resections were R0 in 2, R1 in 6 pts. 9 pts were not operated (4 with age > 75 and multiple co-morbities, 4 due to advanced T, 1 still on neoadjuvant IM). One patient was never treated. T characteristics were: KIT+ (n = 15), CD34+ (n = 8), mitoses/50 HPF ≤ 5 (n = 2), mitoses /50 HPF > 5 (n = 6), and mitoses count unknown for 9. Mutations were documented in 11/17 cases, usually in KIT exon 11 (82%). Five pts received adjuvant IM. With a median follow-up of 19 months (7-99), 12 pts are alive, 5 died (4 due to other cause). Two pts relapsed after enucleation, with metastases in one. Among 12 pts alive, 5 are in CR, 7 with measurable disease (4 in PR, 3 with SD) still on IM for 5, on other TKI for 1, and 1 never treated. Conclusions: ESOGIST must be differentiated from leiomyoma and can be reliably identified pre-operatively by EUS-guided biopsy. Surgery for ESOGIST is either enucleation or oesophagectomy depending on tumor size. Preoperative IM therapy may improve resectability and is an efficient alternative when surgery is contraindicated
FRI-508-How reliable is initial liver resection before salvage liver transplantation and what are the predictors of dropout?
Authors: Soon Ho Um, Chung Gyo Seo, Sun Young Yim, Yoo Jin Lee, Young Dong Yu, Dong Sik Kim, Tae Hyung Kim, Hyung Joon Yim, Ji Hoon Kim, Yeon Seok Seo
Journal: Journal of Hepatology (2019)
FRI-228-Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention) study
Authors: Joseph Doyle, Paul Dietze, Mark Stoove, Peter Higgs, Paul Desmond, David Iser, Emma Mcbryde, Brendan Harney, Alisa Pedrana, Tim Spelman, Sally Von Bibra, Janine Roney, Alexander Thompson, Margaret Hellard
Journal: Journal of Hepatology (2019)
TCTAP A-046 Door to Wire Crossing Time and Corrected TIMI Frame Count Local Intracoronary Single Bolus Administration of Thrombolytic Alteplase in Primary PCI in Acute STEMI Within 12 Hours of Symptom Onset
Authors: Zulfikri Mukhtar, Harris Hasan, Sutomo Kasiman, Nizam Zikri Akbar, Henry Panjaitan, Teuku Bob Haykal
Journal: Journal of the American College of Cardiology (2019)
Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Authors: Christof Bernemann, Verena Humberg, Barbara Thielen, Julie Steinestel, Xin Chen, Stefan Duensing, Andres J. Schrader, Martin Boegemann
Journal: Clinical Cancer Research (2019)

Androgen receptor splice variants are known to facilitate resistance of prostate cancer cells toward antihormonal therapies. However, detection of the most prominent variant, AR-V7, on its own, is not sufficiently accurate for prediction of response. Thus, simultaneous detection of other variants might improve prediction. AR-V567es has been shown to be expressed in late stages of prostate cancer. Yet, there have been discrepant results regarding incidence of AR-V567es. We therefore aimed to perform a comprehensive comparison of different detection approaches for AR-V567es mRNA.We compared a custom-made, probe-based PCR assay with 6 published AR-V567es detection PCR assays in distinct samples, that is, cancer cell lines, LuCaP xenografts, primary and metastatic tumor samples, and circulating tumor cells (CTC).Using distinct approaches, we concordantly detected expression of AR-V567es in only three of 45 samples (LuCaP xenografts 86.2 and 136s2 as well as one CTC sample). We observed varying results in all other samples. Specificity analysis displayed nonspecific binding of 5 previously published PCR assays to AR full-length mRNA in the absence of AR-V567es.Validation of biomarker detection approaches is one of the most critical steps before transfer into clinical application. By performing comparative analysis of different detection approaches, we revealed eminent variability among previously described systems. Furthermore, we demonstrate an overestimation of AR-V567es in prostate cancer, presumably due to nonspecific detection of AR-FL mRNA. Therefore, any correlation between AR-V567es expression and clinical responses is highly doubtful and does not reflect the biological nature of the disease.
Revisiting Cytochemical Myeloperoxidase (MPO) Stain for Early Diagnosis of Acute Promyelocytic Leukemia (APML) in Areas with Limited Resources: An Experience from a Tertiary Care Center in India
Authors: Annapurna Saksena, Parth Desai, Vishal Chauhan, Naresh Gupta, Tejinder Singh
Journal: Blood (2017)
Therapeutic Use Exemptions (TUEs) are essential in sport: but there is room for improvement
Authors: Ken Fitch
Journal: British Journal of Sports Medicine (2019)

Hacking of the World Anti-Doping Agency’s (WADA’s) Anti-Doping Administrative & Management System (ADAMS) by an alleged Russian cyber espionage group ‘Fancy Bear’ disclosed incomplete information about Therapeutic Use Exemptions (TUEs) granted to more than 100 Olympic athletes from over 20 countries1 including some high-profile athletes. These unethical and illegal leaks of personal medical information provoked some criticism of the TUE system, much of it is ill-informed.2 3 In this discussion, I briefly review the concept of TUEs and advise how the TUE system can and should be strengthened.

The TUE concept is both sound and essential, and the four criteria that must be met to approve a TUE have changed only marginally in 25 years4 (online appendix 1a).

### Supplementary data

[bjsports-2018-100113supp001.pdf] 

After WADA approved the TUE guidelines in 2004 (that the IOC had adopted in 1991), WADA developed TUE Physician Guidelines —a valuable resource that currently outlines 19 of the different medical conditions that may necessitate an application for a TUE.5 These are updated regularly. TUEs are required to be uploaded …
Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients
Authors: Maria A.S. Broggi, Lea Maillat, Cristina C. Clement, Natacha Bordry, Patricia Corthésy, Aymeric Auger, Maurice Matter, Romain Hamelin, Lambert Potin, Davide Demurtas, Emanuela Romano, Alexandre Harari, Daniel E. Speiser, Laura Santambrogio, Melody A. Swartz
Journal: The Journal of Experimental Medicine (2019)

Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137+ and stem cell-like types. In mice, lymph vessels were the major route of extracellular vesicle transport from tumors to the systemic circulation. We suggest that lymphatic exudate provides a rich source of tumor-derived factors for enabling the discovery of novel biomarkers that may reflect disease stage and therapeutic response.
Decontamination Strategies for Critically Ill Patients—Reply
Authors: Bastiaan H. Wittekamp, Nienke L. Plantinga, Marc J. M. Bonten
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inflammatory breast cancer in Morocco: Biological features and outcome.
Authors: Zineb Benbrahim El Mekkeoui, Nabil Ismaili, Samia Arifi, Naima Abda, Said Afqir, Hassan Errihani, Nawfel Mellas
Journal: Journal of Clinical Oncology (2015)

e12039 Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer characterized by rapidly progressive breast mass, skin changes, and regional adenopathy. This rare disease has been classically confused with non inflammatory locally advanced breast cancer and its prevalence was estimated previously at 15% of breast cancers in North Africa. The objective of this study was to review the actual prevalence, characteristics and outcomes of IBC in Morocco. Methods: We retrospectively reviewed data of 220 IBC patients who received care at 3 Oncology centers in Morocco during a period of 3 years. Data were statistically described in terms of means, standard deviations, medians and frequencies. Kaplan-Meier method was used to estimate median event free survival (EFS) and overall survival (OS). Results: IBC patients represent 6% of all breast cancers (220/3540). The mean age of patients was 47.6 years (±10.8). 57.75% of patients had premenopausal status. 65 % of the cases had clinical lymph nodes and 29.8% had metastases at diagnosis. The dominant pathological type was infiltrating ductal carcinoma (90.6%). Most patients had high grade II/III (93.8 %). The immune-histochemical study showed that 72 % of the tumors were classified as luminal, 9.5% as Her2 overexpressing and 14.7% as triple negative. 68.75% of patients with non metastatic IBC received sequential chemotherapy with a mean number of cycles of 6.3. 88.8% had clinical objective response and underwent local therapy. The overall pCR rate was 10%. 11.11% of patients with non metastatic IBC had progressive disease and underwent concomittent radiochemotherapy. The median EFS was 15.29 months (95% CI: 4.99 – 25.59) and median OS was 18.29 months (95% CI: 7.39 – 29.19). In metastatic IBC, 54.55% of patients received anthracyclines and taxanes based chemotherapy. The objective response rate was 73.6%. 18.18% of the patients underwent local therapy. The median EFS was 9.2 months (95% CI: 4 – 13.4) and median OS was 13.8 months (95% CI: 3–23.8). Conclusions: IBC represents 6% of breast cancer in Morocco. Although a high responsiveness to chemotherapy, IBC are characterized with their poor prognosis. To improve outcome, further specific therapeutic strategies have to be developed.
Abstracts of the 10th George Rajka International Symposium on Atopic Dermatitis, 11-13 April 2018, Utrecht, the Netherlands
Authors: John Chittock, Kirsty Brown, Michael Cork, Simon Danby
Journal: British Journal of Dermatology (2018)

of Quantification of natural moisturizing factors at the skin surface using a portable infrared spectrometer device: a pilot, calibration model.